The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer
Prashanth Ashok Kumar,Alina Basnet
DOI: https://doi.org/10.21037/tlcr-23-566
2023-09-28
Translational Lung Cancer Research
Abstract:Prashanth Ashok Kumar ^ , Alina Basnet Division of Hematology-Oncology, Upstate Cancer Center, Upstate Medical University, Syracuse, NY, USA ^ ORCID: 0000-0001-6236-2822. Comment on: Sung M, Jang WS, Kim HR, et al . Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy. Transl Lung Cancer Res 2023;12:1506-16. Keywords: Immune-checkpoint therapy; neutrophil-lymphocyte ratio (NLR); C-reactive protein (CRP); lactate dehydrogenase (LDH); non-small cell lung cancer (NSCLC) Submitted Aug 31, 2023. Accepted for publication Sep 08, 2023. Published online Sep 14, 2023. doi: 10.21037/tlcr-23-566 Immune-checkpoint inhibitors (ICIs) like pembrolizumab, atezolizumab, ipilimumab, nivolumab, durvalumab, avelumab, and cemiplimab have been approved in non-small cell lung cancer (NSCLC) in various disease stages. Their use has exponentially increased in the past decade (1). Combination of ICI with platinum based chemotherapeutic agents is one of the standards of care in the metastatic setting regardless of the programmed death-ligand 1 (PD-L1) expression on the tumor (2). Pembrolizumab (Keytruda) is approved for use as a single-agent immunotherapy in NSCLC patients with PD-L1 expression of ≥1%, including those with ≥50% expression (3,4). Over the past decade, a concomitant endeavor has unfolded, aimed at integrating ICIs into clinical scenarios, such as the perioperative milieu and the post-concurrent chemoradiation therapy landscape, thus reflecting an evolving frontier in therapeutic exploration (4-6). This includes the landmark PACIFIC trial that showed a clear improvement in response rate (RR), duration of response (DOR), and overall survival (OS), with 1 year use of durvalumab post concurrent chemo-radiation therapy in unresectable stage III NSCLC (5). Routine practice also involves utilizing atezolizumab or pembrolizumab as adjuvant therapy post-resection and adjuvant chemotherapy, notably in patients with PD-L1 expression ≥1% (7,8). The CheckMate 816 trial then has paved the way for the utilization of nivolumab in the neoadjuvant context, specifically catering to patients with resectable stage IB–IIIA disease, marking a significant advancement in treatment strategies. Compared to chemotherapy alone, addition of nivolumab demonstrated longer event-free survival (EFS) and better pathological complete response (pCR) rate (6). With an explosion in the number of indications of ICIs use, it becomes important to carefully select patients who will benefit, as ICIs can cause life-threatening autoimmune adverse effects like pneumonitis, colitis, myocarditis, and encephalitis at any point of time during and after therapy (9). Several attempts, hence are ongoing to conduct studies that are analyzing the prognostic and predictive use of various biomarkers including PD-L1 and tumor mutational burden (TMB) expressed on the tumor itself (10). Some of these include clinical and pathological characteristics like gender, body weight, type and location of metastasis, steroid and antibiotic use, blood-based laboratory tests like neutrophil-lymphocyte ratio (NLR), lactate dehydrogenase (LDH), C-reactive protein (CRP), vascular endothelial growth factor (VEGF), and tumor specific factors like circulating DNA, soluble plasma PD-L1, TMB, and mutations like TP53 and STK11 / KEAP1 (11). With the above background, we review a recently published study in this journal. Sung et al. performed a single institutional retrospective analysis of NSCLC patients who received ICI like ipilimumab, nivolumab, pembrolizumab, and atezolizumab, to study the utility of NLR, LDH, and CRP (12). They utilized data from 597 patients between 2010 and 2021. Based on survival at 1 year, patients were divided into two groups. The study did have a relatively large number of patients who did not survive at 1 year (55.6%), which is slightly lower that than historical ICI clinical trials (60–70%) (1,2), indicating that the cohort may have had patients with aggressive disease and poor prognosis to begin with. Most of the patients in both groups were metastatic NSCLC (>95%). Baseline characteristics between the groups were well matched except for Eastern Cooperative Oncology Group (ECOG), which was higher for the non-survival group, which by itself could have contributed to the mortality. The parameters were recorded at baseline, which the authors define as 14 days before the first ICI initiation, and early ICI period which they define as 8 weeks from stating the medication. Abnormal values were clearly defined (NLR >4, CRP >8 mg/dL, and LDH >247 IU/L). As the disease course progressed from the baseline to early treatment phase, NLR, CRP, and LDH rose with statistical significance in th -Abstract Truncated-
oncology,respiratory system